VA
GPCR icon

Verdad Advisers’s Structure Therapeutics GPCR Stock Holding History

Verdad Advisers’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$546K Buy
+11,335
New +$776K 0.62% 58

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Verdad Advisers's GPCR Position: Q1 2026 in Review

Verdad Advisers opened a new position in Structure Therapeutics (GPCR) in Q1 2026: 11,335 shares worth $546K. The stake represents 0.62% of the portfolio and ranks #58 among its holdings.

196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Verdad Advisers held 11,335 shares of Structure Therapeutics worth $546K as of Q1 2026.
  • Structure Therapeutics was a new Verdad Advisers position in Q1 2026.
  • Structure Therapeutics made up 0.62% of Verdad Advisers's portfolio in Q1 2026, its #58 holding.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.